Fig. 1From: Efficacy and safety during extended treatment of lesinurad in combination with febuxostat in patients with tophaceous gout: CRYSTAL extension studyProportion of patients with serum urate (sUA) < 5.0 mg/dl (a) and mean (SE) sUA levels (b) in the core study and extension study: observed cases (intention-to-treat population). CONT Continuation of lesinurad treatment, CROSS Crossover from core study placebo to lesinurad treatmentBack to article page